| Literature DB >> 30416522 |
Meng Zhao1,2,3, Xiaohan Zhang1,2,3, Ling Gao2,3,4, Yongfeng Song1,2,3, Chao Xu1,2,3, Chunxiao Yu1,2,3, Shanshan Shao1,2,3, Jiajun Zhao1,2,3.
Abstract
Our previous studies suggested that the thyroid might be a target organ affected by lipotoxicity, which might be partially related to the increasing prevalence of subclinical hypothyroidism. However, the underlying molecular mechanism is not yet clearly established. This study aimed to assess the effect of palmitic acid stimulation on thyrocyte function. Upon palmitic acid stimulation, intracellular contents of lipids, as well as the expression and activity of three key molecules in thyroid hormone synthesis (i.e., thyroglobulin, sodium iodide symporter, and thyroperoxidase), were determined in human primary thyrocytes. The contents of BODIPY® FL C16 (the fluorescently labeled palmitic acid analogue) entering into the thyrocytes were gradually increased with time extending. Accordingly, the intracellular accumulation of both triglyceride and free fatty acids increased in dose- and time-dependent manners. The effect of palmitic acid stimulation on thyroid hormone synthesis was then determined. Both the mRNA and protein levels of thyroglobulin, sodium iodide symporter, and thyroperoxidase were decreased following palmitic acid stimulation. Consistently, upon palmitic acid stimulation, the secreted thyroglobulin levels in supernatants, 131I uptake, and extracellular thyroperoxidase activity were all decreased in a dose-dependent manner. Our results demonstrated that upon palmitic acid stimulation, the expressions of the key molecules (thyroglobulin, sodium iodide symporter, and thyroperoxidase) were reduced and their activities were suppressed, which might lead to impaired thyroid hormone synthesis.Entities:
Year: 2018 PMID: 30416522 PMCID: PMC6207890 DOI: 10.1155/2018/4215848
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Primers for quantitative real-time PCR in the study.
| NM | Product (bp) | Forward (5′ to 3′) | Reverse (5′ to 3′) | |
|---|---|---|---|---|
| Human NIS | 000453.2 | 180 | GTCCTTCAGGGCTCCTTCACC | CTGCTCGCTGGGTGGGTACA |
| Human TPO | 000547.5 | 241 | CTGTCTGTCACGCTGGTTATGG | TCACTCCGCTTGTTGGCTCA |
| Human Tg | 003235.4 | 203 | TTCTTTGAATGTGAACGACGGTG | AAGGGATAGGTGTGGACTTCAATGT |
| Human BiP | 005347.4 | 150 | GCCTGTATTTCTAGACCTGCC | TTCATCTTGCCAGCCAGTTG |
| Human | 001101 | 104 | ACAGAGCCTCGCCTTTGCCG | ACATGCCGGAGCCGTTGTCG |
NIS: sodium iodide symporter; TPO: thyroperoxidase; Tg: thyroglobulin; BiP: binding immunoglobulin protein.
Figure 1Palmitic acid increases the intracellular triglyceride and free fatty acid contents in human thyrocytes. (a) Intracellular distribution of BODIPY® FL C16, the fluorescently labeled palmitic acid analogue (1 μM) in cells with time extending. Scale bars, 20 μm. (b) Upper: dose-dependent intracellular accumulations of triglyceride and free fatty acid in cells exposed to palmitic acid for 24 hours (n = 4). Lower: time-dependent intracellular accumulations of triglyceride and free fatty acid in cells exposed to palmitic acid at the concentration of 0.2 mM (n = 3). All data are expressed as the mean ± standard deviation. ∗∗ P < 0.01 versus human primary thyrocytes without palmitic acid stimulation. # P < 0.05 and ## P < 0.01 versus human primary thyrocytes with palmitic acid stimulation at 0.2 mM or for 12 hours. The error bars represent the standard deviations.
Figure 2The process of thyroid hormone synthesis.
Figure 3Palmitic acid downregulates the expression of thyroglobulin (Tg), sodium iodide symporter (NIS), and thyroperoxidase (TPO) in human primary thyrocytes. (a) The mRNA levels of Tg, NIS (SLC5A5), and TPO in cells stimulated with palmitic acid for 24 hours (n = 3 to 5). (b) Dose-dependent effects of palmitic acid on the protein levels of Tg, NIS, and TPO for 72 hours detected by Western blot. (c) The protein levels of Tg, NIS, and TPO detected by immunofluorescence in cells stimulated with palmitic acid at 0.2 mM for 72 hours. Scale bars, 20 μm. (d) The relative protein levels from Western blot assays for Tg, NIS, and TPO was quantified by densitometry and normalized with GAPDH. (e) The relative fluorescence intensity from immunofluorescence assays for Tg, NIS, and TPO. In all panels, representative data from 3 to 7 independent experiments are shown. All data are expressed as the mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01 versus human primary thyrocytes without palmitic acid stimulation; # P < 0.05 versus human primary thyrocytes stimulated with palmitic acid at 0.2 mM. The error bars represent the standard deviations. PA: palmitic acid; Tg: thyroglobulin; SLC5A5: gene name of sodium iodide symporter; TPO: thyroperoxidase.
Figure 4Palmitic acid downregulates the activity of thyroglobulin (Tg), sodium iodide symporter (NIS), and thyroperoxidase (TPO) in human primary thyrocytes. (a) Secreted Tg levels in supernatants of cells stimulated with palmitic acid for 72 hours (n = 7). The Tg levels were normalized with corresponding protein amount. (b) The effects of palmitic acid stimulation on 131I uptake for 72 hours (n = 7). 131I uptake values were normalized with corresponding cell counts. (c) Extracellular TPO activity of the cells stimulated with palmitic acid for 72 hours (n = 6). Enzymatic activity values were normalized with corresponding protein amount. In all panels, representative data from 3 to 7 independent experiments are shown. All data are expressed as the mean ± standard deviation. ∗ P < 0.05 and ∗∗ P < 0.01 versus human primary thyrocytes without palmitic acid stimulation. The error bars represent the standard deviations. PA: palmitic acid; RFU: relative fluorescence unit.